This is a preview of subscription content, log in via an institution to check access.
Notes
BRL = Brazilian reals
Reference
Tsuchiya CT, et al. Estimating the Potential Budget Impact of Zelboraf (Vemurafenib) for Advanced Melanoma Treatment in Brazilian Private Health Care System. 18th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research : abstr. PCN26, 18 May 2013.
Rights and permissions
About this article
Cite this article
Targeted use of vemurafenib = low budget impact in Brazil. PharmacoEcon Outcomes News 680, 2 (2013). https://doi.org/10.1007/s40274-013-0460-0
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-013-0460-0